dataFormula C20H30NO3Mol. mass 389.457 g/molSMILES eMolecules & PubChemPharmacokinetic dataBioavailability ?Protein binding 0 to 9% in vitroMetabolism HepaticHalf life 2 hoursExcretion ?Therapeutic 13 atrovent hfa 13 atrovent hfa B(US)Legal status POM(UK)Routes InhalationIpratropium (as ipratropium bromide, trade name.

8-azoniabicyclo[3.2.1] oct-3-yl] 3-hydroxy-2-phenyl-propanoateIdentifiersCAS number 60205-81-4ATC code R01AX03 R03BB01PubChem 43232DrugBank APRD00537Chemical 13 atrovent hfa C20H30NO3Mol. mass 389.457 g/molSMILES eMolecules & PubChemPharmacokinetic dataBioavailability ?Protein 13 atrovent hfa 0 to 9% in vitroMetabolism 13 atrovent hfa life 2 hoursExcretion ?Therapeutic considerationsPregnancy cat. B(US)Legal status POM(UK)Routes InhalationIpratropium (as ipratropium bromide, trade name Atrovent) is an 13 atrovent hfa drug administered by inhalation for the treatment of 13 atrovent hfa lung diseases. It acts by blocking muscarinic receptors in the lung, inhibiting bronchoconstriction and mucus secretion. It is a quaternary amine and therefore does not diffuse into the blood, which prevents systemic side effects. 13 atrovent hfa is also combined with albuterol (salbutamol) (trade names Combivent and Duoneb) 13 atrovent hfa the treatment of obstructive lung diseases. It acts by blocking muscarinic receptors in the.

dogs (author's transl)]" (in Japanese). Nippon Yakurigaku Zasshi 73 (7): 785-91. PMID 145994.